Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ANVS by emailGet an email when ANVS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ANVS, unsubscribe in one click. Privacy
📣 What ANVS Says Is Next
fourth quarter of 2026 · “The disease-modifying data readout is anticipated 18 months after the last patient is dosed. · PD OLE study : Annovis expects to complete enrollment for the PD OLE study in the fourth quarter of 2026. · NDA pathway : Based on the Phase 3 AD study outcomes, Annovis plans to engage with the FDA regarding a regulatory NDA submission for buntanetap as a symptomatic treatment for AD in early 2027 and as a disease-modifying treatment in early 2028.”
Company press release, May 15, 2026 · SEC filing
early 2027 · “The first symptomatic efficacy readout is anticipated in early 2027, followed by a disease-modifying readout expected in early 2028.”
Company press release, Feb 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ANVS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANVS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.